financetom
Business
financetom
/
Business
/
Enovix Establishes R&D Center in India to Accelerate Development of Battery Platform
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Enovix Establishes R&D Center in India to Accelerate Development of Battery Platform
Aug 8, 2025 7:08 AM

09:47 AM EDT, 08/08/2025 (MT Newswires) -- Enovix ( ENVX ) said Friday it has established an R&D center in Hyderabad, India to boost the development of its second-generation battery platform AI-2.

Employees at the new 18,000-square-foot R&D facility will use battery modeling and machine learning to accelerate the first prototypes on Enovix's ( ENVX ) AI-2 platform for engineering evaluation this year, the company said.

Financial details were not disclosed.

Price: 11.09, Change: +0.09, Percent Change: +0.82

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
What's Going On With Insurance Company Loews' Shares Monday?
What's Going On With Insurance Company Loews' Shares Monday?
May 6, 2024
Loews Corp ( L )  reported first-quarter FY24 net income of $457 million, up 22% Y/Y. EPS of $2.05 was higher than the year-ago figure of $1.61. Revenues were $4.23 billion, higher than $3.78 billion a year ago. CNA Financial Corp ( CNA ) revenue contribution increased to $3.44 billion from $3.15 billion a year ago, and net income rose to $310 million from $268...
VYNE Therapeutics Says US FDA Clears its Investigational New Drug Application for Potential Autoimmune Treatment
VYNE Therapeutics Says US FDA Clears its Investigational New Drug Application for Potential Autoimmune Treatment
May 6, 2024
08:51 AM EDT, 05/06/2024 (MT Newswires) -- VYNE Therapeutics ( VYNE ) said Monday the US Food and Drug Administration has cleared its Investigational New Drug Application for VYN202, its potential autoimmune disease treatment Vyne said it plans to initiate a first-in-human phase 1a trial of VYN202 in healthy volunteers in Q2 and report top line results from the trial...
Garrett Motion Units to Offer $500 Million Senior Unsecured Notes Due 2032
Garrett Motion Units to Offer $500 Million Senior Unsecured Notes Due 2032
May 6, 2024
08:53 AM EDT, 05/06/2024 (MT Newswires) -- Garrett Motion ( GTX ) said Monday its Garrett Motion ( GTX ) and Garrett LX units are planning to launch a private offering of $500 million total principal amount of senior unsecured notes due 2032. The company intends to utilize the proceeds, plus its cash on hand, to repay term loan indebtedness...
Lyra Therapeutics Phase 3 Trial of LYR-210 Falls Short of Primary Endpoint, Plans to Cut Staff; Shares Drop Pre-Bell
Lyra Therapeutics Phase 3 Trial of LYR-210 Falls Short of Primary Endpoint, Plans to Cut Staff; Shares Drop Pre-Bell
May 6, 2024
08:52 AM EDT, 05/06/2024 (MT Newswires) -- Lyra Therapeutics ( LYRA ) said Monday that the phase 3 of its Enlighten 1 trial, evaluating the company's investigational treatment LYR-210 for chronic rhinosinusitis, failed to meet its primary endpoint at 24 weeks. The drug candidate was generally well tolerated, with no product-related serious adverse events. Data from an ongoing 52-week extension...
Copyright 2023-2026 - www.financetom.com All Rights Reserved